Inhibiting <scp>H3K27</scp> Demethylases Downregulates <scp>CREB</scp> ‐ <scp>CREBBP</scp> , Overcoming Resistance in Relapsed Acute Lymphoblastic Leukemia
This study proposes H3K27 demethylase inhibition as a potential treatment strategy for patients with treatment-resistant ALL, using CREBBP as a biomarker for drug response and combining GSK-J4 with venetoclax and navitoclax as synergistic partners.
Authors
- Joan Montero (ORCID: https://orcid.org/0000-0002-9192-4836)
- Lina Alasfar (ORCID: https://orcid.org/0000-0001-8125-5723)
- Claudia Dorothea Baldus (ORCID: https://orcid.org/0000-0002-0748-834X)
- Lorenz Bastian (ORCID: https://orcid.org/0000-0002-1487-9437)
- Kathy Astrahantseff
- Mathurin Dorel (ORCID: https://orcid.org/0000-0002-1663-2075)
- Clara Alcon (ORCID: https://orcid.org/0000-0003-3243-9440)
- Marie‐Laure Yaspo (ORCID: https://orcid.org/0000-0002-9555-9979)
- Juan José Lázaro (ORCID: https://orcid.org/0000-0002-2324-7159)
- Cornelia Eckert (ORCID: https://orcid.org/0000-0003-1039-2872)
Institutions
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (ES)
- University Hospital Schleswig-Holstein (DE)
- Max Planck Institute for Molecular Genetics (DE)
- Universitat de Barcelona (ES)
- Charité - Universitätsmedizin Berlin (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/cam4.70596
- Citations
- 2
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 3.76
Funders
- Generalitat de Catalunya
- Ministerio de Ciencia e Innovación
- José Carreras Leukämie-Stiftung
- Agència de Gestió d'Ajuts Universitaris i de Recerca